

Bilski Pharma Sample

S.No.	Patent/Publication No.	Application Date	Date of Publication	Date of rejection	FR or N/FR	Rejection type	101 Rejection	102 Rejection	103 Rejection
1	US20050220771A1	3/24/2005	10/6/2005	12/5/2008	N/FR	102, 103 and 112 rejections	N/A	Claims 130-133 are rejected under 35 U.S.C. 102(b) as being anticipated by US 20040259966 (?966).	Claims 130-135 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 5885234 (?234) in view of US 20040249327 (?327).
2	US20050260243A1	4/25/2005	11/24/2005	1/16/2009	FR	103 rejections	N/A	N/A	1. Claims 1-5, 7-10 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Beerse et al. (US Patent 6,190,675B1) in view of Tautvydas et al. (WO 01143549 A2; cited in the IDS). 2. Claims 1 and 5-6 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Beerse et al. (US Patent 6,190,675B1) in view of Tautvydas et al. (WO 01143549 A2; cited in the IDS), further in view of Diehl et al. (US Patent 5,591,442).
3	US20050261189A1	4/18/2005	11/24/2005	10/15/2007	N/FR	101, 102, 103 and 112 rejections	Claim 43 is rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101	1. Claims 1-4, 7-10, 13,14, 17-19, and 21 are rejected under 35 U.S.C. 102(b) as being anticipated by WO 200017326 A1, March 30,2000 (of record). 2. Claims 1-10, 17-19,2 1,23-30, 32,33-37, and 40-43 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent ~ ~ p l i c a t i o 20n0 60 1 15464, filed with a claim of priority to June 25, 2003	1. Claims 11 and 12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Application 200601 15464 as applied to claims 1-10,23-30,32, 33, 35-37,40,41, and 43 above, and further in view of Reichsman et al., J. Cell Biol. 1996 135: 819-827. 2. Claims 20 and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Application 200601 15464 as applied to claims 1-10,23-30, 32, 33, 35-37?, 40,41, and 43 above, and further in view of US Patent 159462, ~ecembe1r 2,2000
4	US20060079574A1	10/7/2005	4/13/2006	5/17/2006	N/FR	101, 102 and 112 rejection	Claim 7 is rejected under 35 U.S.C. 101 as claiming the same	Claims 1-1 0 are rejected under 35 U.S.C. 102(b) as being anticipated by Weiss	N/A

							invention as that of claim 2 of prior U.S. Patent No. 5,925,672 of record.	(U.S. Patent No. 5,208,244) of record.	
5	US20050209181A1	11/4/2004	9/22/2005	7/14/2008	FR	112 rejection	N/A	N/A	N/A
6	US20050249704A1	12/22/2004	11/10/2005	6/11/2008	FR	103 and 112 rejections	N/A	N/A	1. Claims 1, 3-6, 8-10, 12-14, 16-17, and 19-28 remain rejected under 35 USC 5 103(a) as being obvious in view of the combination of Nakatani et al ("Nakatani"), Vincenti et al ("Vincenti"), Hayosh et al ("Hayosh"), Paty et al ("Paty") and Jacobs et al ("Jacobs"), as set forth on pages 4-7 of the office action mailed on 1/30/2007. 2. Claims 1, 3-6, 8-14, 16-17, and 19 remain rejected, and amended/new claims 20-26 are also rejected, under 35 USC § 103(a) as being obvious in view of the combination of the "Study of Zenepax" document, Khoury et al ("Khoury"), Paty et al ("Paty"), and Jacobs et al ("Jacobs"), as set forth on pages 7-9 of the office action mailed on 8/11/2006.
7	US20050249823A1	10/28/2004	11/10/2005	3/24/2008	N/FR	102 and 103 rejections	N/A	Claims 1, 5-14, and 17 are rejected under 35 U.S.C. 102(b) as being anticipated by Hermelin et al. (US Patent No. 6258846).	Claims 2-3 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hermelin et al. in view of Kiliaan et al. (US PG PUB No. 200210040058).
8	US20050250688A1	10/22/2003	11/10/2005	8/7/2007	FR	103 rejection	N/A	N/A	Claim 25 is rejected under 35 U.S.C. 103(a) as being unpatentable over Toledo-Pereyra (Klin Wochenschr, 1991, 69: 1099-1 104) in view of Benedict et al. (of record on the 9/20/04 IDS) and in view of the product use sheet from l ,5-dansyl-Glu-Gly-Arg chloromethyl ketone from Calbiochem (revision 27 May 1997).
9	US20050260161A1	3/8/2005	11/24/2005	4/21/2008	FR	102, 103 and 112	N/A	Claims 46-47,49-51	Claim 48 is rejected under 35 U.S.C.

						rejections		and 54 are rejected under 35 U.S.C. 102(b) as being anticipated by Eriksson et al. (WO 00127879).	103(a) as being unpatentable over Eriksson et al. (WO 00127879) in view of Alitalo et al. (WO 01162942).
10	US20060014719A1	7/13/2005	1/19/2006	7/25/2006	N/FR	112 rejection	N/A	N/A	N/A
11	US20060014165A1	1/26/2005	1/19/2006	6/18/2008	FR	112 rejection	N/A	N/A	N/A
12	US20060019890A1	1/18/2005	1/26/2006	8/10/2007	N/FR	102, 103 and 112 rejections	N/A	Claims 1-8 are rejected under 35 U.S.C. 102(b) as being anticipated by Burger et al. (American Heart Journal, December 2002).	Claims 1-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hayashi et al. (JACC Abstracts, February 2000, citation 4 in the IDS of 8/12/05) in view of Ogawa et al. (Can J Physiol Pharmacol, 2001).
13	US20060116315A1	7/18/2005	6/1/2006	9/24/2007	FR	102 and 112 rejections	N/A	Claims 2 and 15-19 are rejected under 35 U.S.C. 102(e) as being anticipated by Lee et al., US 2003/0224450, filing date of 08/12/2001 for reasons of record as applied to claim 2 in section 10 of Paper mailed on April 2, 2007.	N/A

14	US20060210541A1	5/26/2006	9/21/2006	4/23/2008	FR	103 rejection	N/A	N/A	Claims 1,2, 5, 6, 8, and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cutler (WO 98109644) taken with Wilson et al. (US 5,866,552).	
15	US20060211769A1	5/24/2006	9/21/2006	2/9/2007	FR	112 rejection	N/A	N/A	N/A	
16	US20060211020A1	2/22/2006	9/21/2006	6/27/2008	N/FR	112 rejection	N/A	N/A	N/A	
17	US20070010435A1	1/26/2006	1/11/2007	8/7/2008	N/FR	102, 103 and 112 rejections	N/A	Claims 1-3, 5-7, 10 and 13 are rejected under 35 U.S.C. 102(b) as being anticipated by WO 99127944 to Schenk (Cite No. BE on Applicants? IDS dated 17 October 2005).	Claims 14 and 15 are under 35 U.S.C. 103(a) as being unpatentable over WO99127944 to Schenk, in view of Carro et al. (citation CS on IDS dated 17 October 2005).	

18	US20070049614A1	4/17/2006	3/1/2007	10/31/2007	FR	103 and 112 rejections	N/A	N/A	Claims 1 - 11 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bradette et al., Gastroenterology, and Caras et al., Gastroenterology, in view of Stacher et al., British Journal of --- Clinical Pharmacology.	
19	US20050209300A1	9/13/2004	9/22/2005	N/A	N/A	Examination information not available	N/A	N/A	N/A	
20	US20050208054A1	12/9/2004	9/22/2005	N/A	N/A	Examination information not available	N/A	N/A	N/A	
21	US20050249805A1	12/18/2004	11/10/2005	N/A	N/A	Examination information not available	N/A	N/A	N/A	
22	US20060079533A1	2/2/2004	4/13/2006	N/A	N/A	Examination information not available	N/A	N/A	N/A	
23	US20070010484A1	6/23/2006	1/11/2007	N/A	N/A	Examination information not available	N/A	N/A	N/A	
24	US20070054328A1	10/10/2006	3/8/2007	N/A	N/A	Examination information not available	N/A	N/A	N/A	